The global custom antibody market was valued at USD 409.31 million in 2021 and it is predicted to surpass around USD 833.96 million by 2030 with a CAGR of 8.23% from 2022 to 2030.
A custom antibody is designed or produced by the supplier for a specific antigen with the help of 90% purified antigen. Polyclonal and monoclonal antibodies are produced using custom antibody production. The steps of custom polyclonal antibody production are peptide design, designing of peptides, animal immunization, serum collection, titer analysis, and antibody purification. The steps for custom monoclonal antibody production are antigen preparation, immunizations of hybridoma development, hybridoma development fusions, monoclonal production and purification. The custom antibody has better selectivity compared to the normal cultured antibodies.
Custom Abs have a wide range of applications in treating asthma, autoimmune diseases, cancer, poisoning, septicemia, viral infection, and other diseases. The prevalence of these diseases is increasing globally which boosts the market. The treatment with these antibodies is cost-effective. So hospitals and healthcare providers have a high demand for these antibodies accelerating the market growth. Some of the successfully developed custom antibodies are proteins and mixtures, membrane proteins, peptides, methylated antigens, phosphorylated antigens, haptens and small organic molecules.
Moreover, custom antibody production services are used to create and discover new biomarkers which also has a positive impact on the growing market. The growth of personalized medicines has also increased for the treatment of cancer and other chronic diseases. This enhances the usage of custom antibodies, thus driving market growth. In June 2021, a custom rabbit mAB, MonoRab was launched by GenScript. It involves hybridoma technology and mAB sequencing. It has better specificity and better affinity applicable to a wide range of applications. The changing disease profiles, growing government funding and support, advances in biotechnology research, and rising public and private partnerships boost market growth.
The market is segmented based on the type, service, source, application, end user, and region. The type segment is divided into monoclonal antibodies, polyclonal antibodies, and recombinant antibodies. The service segment is divided into antibody development, antibody production and purification, antibody fragmentation and labeling. The source segment is divided into mice and rabbits. The application segment is divided into oncology, infectious diseases, immunology, neurobiology, stem cells, and cardiovascular diseases. The end-user segment is divided into pharma and biotechnology companies, hospitals and clinics, and contract research organizations. Based on regions, the market is further segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
As per the regional analysis research, North America holds the largest market due to the advanced healthcare and research facilities available. In this region the government and biotechnology companies are focused on the advancements of drug design structure, research activities, improvement in the proteomics and genomics sector and increasing development in the therapeutics based on antibodies. The majority of the key players are also present in North America which is the major driving factor for enhancing the market. Asia-Pacific region also holds a significant market due to the improved infrastructure of the healthcare facilities, and better healthcare reimbursement policies. Moreover, the therapeutics industry is also growing in the regions of India and China which spurs the market growth.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 409.31 million |
| Revenue Forecast by 2030 | USD 833.96 million |
| Growth rate from 2022 to 2030 | CAGR of 8.23% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, Service, Source, Application, End user, Region |
| Companies Covered |
Thermo Fisher Scientific Inc., Merck KGaA, Cell Signaling Technology Inc., Rockland Immunochemicals, BioLegend, GenScript, Bio-Rad Laboratories Inc., Abcam PLC, Agilent Technologies, Innovagen Ab, ProMab Biotechnologies, Proteogenix, among others |
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Custom Antibody Market
5.1. COVID-19 Landscape: Custom Antibody Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Custom Antibody Market, By Type
8.1. Custom Antibody Market, by Type, 2022-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Polyclonal Antibodies
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Recombinant Antibodies
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Custom Antibody Market, By Service
9.1. Custom Antibody Market, by Service, 2022-2030
9.1.1. Antibody Development
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Antibody Production & Purification
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Antibody Fragmentation & Labeling
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Custom Antibody Market, By Source
10.1. Custom Antibody Market, by Source, 2022-2030
10.1.1. Rabbit
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Mice
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Custom Antibody Market, By Application
11.1. Custom Antibody Market, by Application, 2022-2030
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Infectious Disease
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Immunology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Neurobiology
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Stem Cells
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Cardiovascular Disease
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Custom Antibody Market, By End user
12.1. Custom Antibody Market, by End user, 2022-2030
12.1.1. Pharmaceutical and Biotechnology Companies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Hospitals and Clinics
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Contract Research Organizations
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Custom Antibody Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Service (2017-2030)
13.1.3. Market Revenue and Forecast, by Source (2017-2030)
13.1.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.5. Market Revenue and Forecast, by End user (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Service (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Source (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.7. Market Revenue and Forecast, by End user (2017-2030)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.8.2. Market Revenue and Forecast, by Service (2017-2030)
13.1.8.3. Market Revenue and Forecast, by Source (2017-2030)
13.1.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.8.5. Market Revenue and Forecast, by End user (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Service (2017-2030)
13.2.3. Market Revenue and Forecast, by Source (2017-2030)
13.2.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.5. Market Revenue and Forecast, by End user (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Service (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Source (2017-2030)
13.2.7. Market Revenue and Forecast, by Application (2017-2030)
13.2.8. Market Revenue and Forecast, by End user (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Service (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Source (2017-2030)
13.2.10. Market Revenue and Forecast, by Application (2017-2030)
13.2.11. Market Revenue and Forecast, by End user (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Service (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Source (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.13. Market Revenue and Forecast, by End user (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Service (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Source (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.15. Market Revenue and Forecast, by End user (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Service (2017-2030)
13.3.3. Market Revenue and Forecast, by Source (2017-2030)
13.3.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.5. Market Revenue and Forecast, by End user (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Service (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Source (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.7. Market Revenue and Forecast, by End user (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Service (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Source (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.9. Market Revenue and Forecast, by End user (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Service (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Source (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.5. Market Revenue and Forecast, by End user (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Service (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Source (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.5. Market Revenue and Forecast, by End user (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Service (2017-2030)
13.4.3. Market Revenue and Forecast, by Source (2017-2030)
13.4.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.5. Market Revenue and Forecast, by End user (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Service (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Source (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.7. Market Revenue and Forecast, by End user (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Service (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Source (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.9. Market Revenue and Forecast, by End user (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Service (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Source (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.5. Market Revenue and Forecast, by End user (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Service (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Source (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.5. Market Revenue and Forecast, by End user (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Service (2017-2030)
13.5.3. Market Revenue and Forecast, by Source (2017-2030)
13.5.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.5. Market Revenue and Forecast, by End user (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Service (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Source (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.7. Market Revenue and Forecast, by End user (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Service (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Source (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.5. Market Revenue and Forecast, by End user (2017-2030)
Chapter 14. Company Profiles
14.1. Thermo Fisher Scientific Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Merck KGaA
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Cell Signaling Technology Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Rockland Immunochemicals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. BioLegend
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. GenScript
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bio-Rad Laboratories Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Abcam PLC
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Agilent Technologies
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Innovagen Ab
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers